Public Employees Retirement Association of Colorado Acquires 48,935 Shares of Cambrex Co. (NYSE:CBM)

Public Employees Retirement Association of Colorado lifted its holdings in shares of Cambrex Co. (NYSE:CBM) by 12.3% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 445,305 shares of the biotechnology company’s stock after purchasing an additional 48,935 shares during the period. Public Employees Retirement Association of Colorado owned 1.32% of Cambrex worth $20,845,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of the stock. First Trust Advisors LP boosted its holdings in shares of Cambrex by 406.7% in the second quarter. First Trust Advisors LP now owns 49,696 shares of the biotechnology company’s stock worth $2,326,000 after acquiring an additional 39,889 shares during the period. Bridge City Capital LLC boosted its holdings in shares of Cambrex by 0.5% in the second quarter. Bridge City Capital LLC now owns 51,711 shares of the biotechnology company’s stock worth $2,421,000 after acquiring an additional 255 shares during the period. Arizona State Retirement System boosted its holdings in shares of Cambrex by 0.7% in the second quarter. Arizona State Retirement System now owns 52,208 shares of the biotechnology company’s stock worth $2,444,000 after acquiring an additional 362 shares during the period. Campbell Newman Asset Management Inc. boosted its holdings in shares of Cambrex by 7.0% in the second quarter. Campbell Newman Asset Management Inc. now owns 15,494 shares of the biotechnology company’s stock worth $725,000 after acquiring an additional 1,008 shares during the period. Finally, Confluence Investment Management LLC boosted its holdings in shares of Cambrex by 3.0% in the second quarter. Confluence Investment Management LLC now owns 110,952 shares of the biotechnology company’s stock worth $5,194,000 after acquiring an additional 3,281 shares during the period.

A number of equities analysts have recently commented on CBM shares. Craig Hallum lowered Cambrex from a “buy” rating to a “hold” rating and set a $60.00 price target for the company. in a report on Monday. Robert W. Baird lowered Cambrex from an “outperform” rating to a “neutral” rating and set a $44.00 price target for the company. in a report on Friday, May 3rd. They noted that the move was a valuation call. William Blair lowered Cambrex from an “outperform” rating to a “market perform” rating and set a $60.00 price target for the company. in a report on Wednesday, August 7th. Zacks Investment Research lowered Cambrex from a “buy” rating to a “hold” rating in a report on Wednesday, July 24th. Finally, First Analysis lowered Cambrex from a “strong-buy” rating to an “outperform” rating and raised their price target for the stock from $45.00 to $55.00 in a report on Tuesday, May 7th. Five investment analysts have rated the stock with a hold rating, one has given a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $52.00.

NYSE:CBM traded up $0.11 during trading hours on Wednesday, hitting $60.21. 36,918 shares of the company’s stock traded hands, compared to its average volume of 405,688. The company has a market cap of $2.02 billion, a price-to-earnings ratio of 21.73, a P/E/G ratio of 4.69 and a beta of 2.36. Cambrex Co. has a 52 week low of $33.80 and a 52 week high of $69.43. The company has a fifty day moving average of $46.96. The company has a current ratio of 2.44, a quick ratio of 1.77 and a debt-to-equity ratio of 0.78.

Cambrex Profile

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms.

Read More: Leveraged Buyout (LBO)

Institutional Ownership by Quarter for Cambrex (NYSE:CBM)

Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply